Clinical Trials Browser

Phase 2 × cemiplimab × Other solid neoplasm × Clear all

Solid Tumors

NCT07234058 2026-02-11

LAG-MAPS

Phase 2 Not yet recruiting

126 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Clinical Trials

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

LAG-MAPS

Immunological Variables Associated to ICI Toxicity in Cancer Patients